Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): Study protocol for a randomised controlled trial

Background: Either benznidazole (BZN) or nifurtimox (NFX) is recommended as equivalent to treat Trypanosoma cruzi infection. Nonetheless, supportive data from randomised trials is limited to individuals treated with BZN in southern cone countries of Latin America. Methods: The goal of this randomise...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2019

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23396

Acceso en línea:

https://doi.org/10.1186/s13063-019-3423-3
https://repository.urosario.edu.co/handle/10336/23396

Palabra clave:

Benznidazole
Nifurtimox
Placebo
Antitrypanosomal agent
Benznidazole
Nifurtimox
Nitroimidazole derivative
Adult
Adverse outcome
Aged
Article
Chagas disease
Controlled study
Disease severity
Drug efficacy
Drug safety
Dyspepsia
Female
Headache
Human
Major clinical study
Male
Medication compliance
Multicenter study
Neuropathic pain
Paresthesia
Polymerase chain reaction
Randomized controlled trial
Serology
Skin manifestation
Therapy effect
Treatment duration
Treatment outcome
Treatment refusal
Trypanosomiasis
Asymptomatic disease
Chagas disease
Colombia
Drug effect
Middle aged
Multicenter study (topic)
Parasitology
Pathogenicity
Randomized controlled trial (topic)
Therapeutic equivalence
Time factor
Trypanosoma cruzi
Young adult
Adult
Aged
Asymptomatic diseases
Chagas disease
Colombia
Female
Humans
Male
Middle aged
Multicenter studies as topic
Nifurtimox
Nitroimidazoles
Randomized controlled trials as topic
Therapeutic equivalency
Time factors
Treatment outcome
Trypanocidal agents
Trypanosoma cruzi
Young adult
Benznidazole
Chagas disese
Nifurtimox
Randomized controlled trial
Trypanosoma cruzi

Rights

License

Abierto (Texto Completo)